Mashhad university of medical sciences

17/03/2022

05/03/2022

🔸 4 نکته برای آماده سازی کودک قبل از تزریق واکسن کووید-19


پویش




Webda.mums.ac.ir

25/08/2021

Creating hope for faster treatment of coronary patients with a special formulation of "Methylene Blue"
With the implementation of Methylene Blue research project in clinical trials in Dr.Shariati and Imam Reza hospitals in Mashhad, shining results have been obtained in the treatment of patients, which has led to the rapid discharge of patients from the hospital.
A member of the faculty of Mashhad University of Medical Sciences and the leader of the research project for the treatment of coronary heart disease patients, in an interview with Webda, stated that Methylene Blue is for patients suffering from m**h hemoglobin and hypoxia due to certain poisonings. Approved by the US Food and Drug Administration for many years, it has been used in the world health system. Increasing the level of oxygen and respiration of patients we have achieved good results in the field of rapid treatment of patients.
Dr. Dariush Hamidi Alamdari continued: "In m**h hemoglobin disease, oxygen transfer by iron is not done three times positively for hemoglobin of red blood cells and m**hylene blue converts three times positive iron to double positive and then oxygen can be connected to iron twice which this It raises the oxygen level of the blood.
"Most patients often have low blood oxygen, which makes it difficult for the patient to breathe," he said. "This drug can help increase blood flow to these patients, and based on this clinical research, a research proposal is proposed." It was presented to the university and approved by the university based on scientific documents and was used as a treatment for Quaid-19 patients in Shariati Hospital, Imam Reza Hospital and Ghaem Hospital. Accelerated the discharge of patients and to some extent reduced mortality.
The medical biochemist of Mashhad University of Medical Sciences stated: Due to the very positive results obtained from clinical trials and the reduction of mortality and speeding up the discharge of patients from the hospital, the Central Committee of the University of Covid 19 recommends the use of this drug in The treatment protocols of corona patients in Mashhad University of Medical Sciences were approved in Mashhad hospitals and the necessary correspondence has been done with the Deputy Minister of Treatment so that according to the proven mechanisms of this drug and its effects on patients, it can enter national protocols. .
Dr. Hamidi Alamdari added: "This drug has a new form in its structure after extensive research and experiments. It has several therapeutic mechanisms. It is an anti-Covid 19 antiviral, destroys the virus and reduces inflammation and oxidative stress, and reduces platelet and clot accumulation." Blood clotting and with increasing oxygen reduces the patient's difficulty in breathing and as a very appropriate and effective drug in the onset of the disease can prevent the severity of the disease.
The faculty member of the Clinical Biochemistry Department of Mashhad University of Medical Sciences noted: In the second and third phase clinical trials in the intervention group, patients received m**hylene blue in addition to standard treatments, which accelerated recovery and rapid discharge from the hospital.
He added: "For 87 patients who did not respond to any conventional treatment and were in a very critical condition, as the last line of treatment for these patients, m**hylene blue was prescribed, which fortunately we managed to save 75 patients from death."
He said: "The formulation of m**hylene blue has been patented in the treatment of corona and can be used in combination with other drugs as a treatment supplement."

13/07/2021

Inventing an effective treatment m**hod in the treatment of patients with coronary heart disease in Mashhad University of Medical Sciences

The faculty member of Mashhad University of Medical Sciences stated: With the implementation of Methylene Blue research project in clinical trials of phase 2 and 3 in Shariati and Imam Reza (AS) hospitals in Mashhad, excellent results were obtained in the treatment of patients, which led to rapid discharge from the hospital and Mortality rate decreased.
Dr. Dariush Hamidi Alamdari, the leader of the research project for the treatment of coronary heart disease using m**hylene blue (approved by Mashhad University of Medical Sciences) in an interview with WebDA, described m**hylene blue as a very safe drug and stated: This drug is for patients with m**h. Hemoglobin is sought after for some poisoning and the blood oxygen in them is reduced and is used for treatment. In m**hemoglobin, the transfer of oxygen by iron is not done three times positively for hemoglobin in red blood cells, and m**hylene blue converts three times positive iron to positively, and then oxygen can be bound to iron twice, which raises the oxygen level of the blood. . The faculty member of Mashhad University of Medical Sciences stated: During my studies on patients and wounds, I noticed the effect of m**hylene blue in increasing oxygen delivery in tissues and led to m**hylene blue being a suitable candidate for increasing oxygen delivery in coronary arteries. It can be prescribed to treat these patients. The faculty member of Mashhad University of Medical Sciences stated: Due to the fact that corona patients have low blood oxygen and have difficulty breathing, this drug can help increase blood supply to these patients, submit a research proposal to the university and Based on scientific documents, it was approved by the university and was used as a treatment for Covid-19 patients in Shariati Hospital, Imam Reza Hospital and Ghaem Hospital, and was able to accelerate the process of discharging patients. Clearly reduce mortality rates.
The faculty member of the Department of Clinical Biochemistry of Mashhad University of Medical Sciences added: "The article related to this proposal has been published in the European Journal of Pharmacology and another article has been accepted as Clinical and Translational Investigation and several other articles have been extracted from this proposal." They discuss the very positive therapeutic results obtained through treatment with m**hylene blue.

13/07/2021

قدردانی وزیر بهداشت از دانشگاه علوم پزشکی مشهد در پشبرد اهداف بهداشتی

13/07/2021

27/06/2021

Iranian ophthalmologists are among the best ophthalmologists in the world in the field of corneal transplantation
The head of the corneal transplant team and a member of the faculty of Mashhad University of Medical Sciences said: "Iranian ophthalmologists are among the best ophthalmologists in the field of corneal transplantation and the quality and results of corneal transplantation in the country are equal to the world's advanced centers."
In an interview with Webda, Dr. Siamak Zarei-Qanavati, stating that the main corneal donation of the eye bank of this university is from people with brain death, noted: So far, out of 1063 brain deaths leading to organ donation in Mashhad, a total of 984 have agreed to corneal donation. It has been equal to 94% of the total donations and since the beginning of Mashhad Eye Bank, all cases of satisfaction, taking into account the corneal tissue indicators and the health of the donor, have led to harvesting and processing.
Dr. Zarei Qanavati stated: "Since the beginning of Mashhad Eye Bank, we have had many donations and receipts in different age groups, with an average age of 40 years for corneal donors, 47 years for the average age of corneal recipients, the youngest and the oldest corneal donor for a girl and a boy." The youngest recipient of a cornea was a 9-month-old infant, the oldest corneal donation by a 71-year-old woman was brain death, and the oldest recipient of a cornea was a 91-year-old woman.
Regarding sending and receiving corneas to and from other cities, Dr. Zarei Qanavati said: "The initial goal of Mashhad Eye Bank was to provide tissue for patients in the east of the country, but nevertheless, Mashhad Eye Bank, despite the limited number of donated tissues to brain death cases, so far It has managed to meet part of the needs of Mashhad's specialized medical centers.
Regarding the 1400 plan of this bank, the head of Mashhad Eye Bank stated: One of the most important plans of Mashhad Eye Bank in 1400 is the beginning of activities in the field of corneal donation from deceased patients (heart death), thus Mashhad Eye Bank will be able to To meet the needs of corneal tissue in specialized ophthalmology centers of Mashhad, to meet the need of connective tissues in the east of the country .
In the end, Dr. Zarei Qanavati said: "The eyes of some needy patients have been staring at the kind hands of the survivors for many years, wishing to see a moment of the beauties of life. By promoting the culture of organ donation, we can shed light on the lives of patients in need of organs and their family members.

23/06/2021

Preparation and production of an effective drug to improve the pulmonary symptoms of Covid-19 disease

Powerful researchers of Mashhad University of Medical Sciences succeeded in preparing and producing an effective drug to improve the pulmonary symptoms of Covid-19 disease under the brand name "Covixir Pars".
Dr. Mehrdad Iranshahi, Professor of Pharmacognosy Department and CEO of Knowledge enterprise Gol Elixir Pars Company located in Mashhad University of Medical Sciences, stated: This drug is produced from the gum of desert Comaii (Ferula foetida), its standardization steps based on active ingredients are accurate. It can be used with the permission of the Food and Drug Administration to help relieve the pulmonary symptoms of Covid 19 patients. The effectiveness of this drug has been proven after one year of clinical study (with the permission of the University Ethics Committee) on more than 500 outpatients and coronary patients.
This researcher of Mashhad University of Medical Sciences stated: Pars coxsavir drug is rich in polysulfide compounds that cause the release of hydrogen sulfide in physiological amounts in the body. In recent years, the role of hydrogen sulfide-releasing drugs in improving the function of the respiratory system and combating viral respiratory diseases has received much attention, and its results have been published in prestigious international journals.
Dr. Iranshahi pointed out: According to authoritative international articles, hydrogen sulfide-releasing drugs reduce the level of cytokines and reduce pneumonia. On the other hand, they prevent the virus from multiplying and entering the lung cells. The effect of hydrogen sulfide-releasing drugs on increasing lung glutathione stores has also been proven.

22/06/2021